Table 3.
Outcome Measures Comparing S1P-RM and Natalizumab Patients
| S1P-RM (n = 20) | Natalizumab (n = 64) | Uncorrected OR (95% CI), p | Corrected OR (95% CI), p | |
| PML-IRIS | ||||
| Occurred, n (%) | 11 (55%) | 58 (90.6%) | 0.14 (0.04-0.49) p = 0.002 | 0.18 (0.04–0.72) p = 0.002a |
| Outcome | ||||
| Short-term outcome mRS at 12 mo, median (IQR25-75) |
3 (2–4) | 3 (2–4) | 0.81 (0.32–2.0) p = 0.649 | 0.18 (0.05, 0.67) p = 0.01b |
| Long-term outcome mRS at last follow-up, median (IQR25-75) |
3 (2–4) | 3 (2–4) | 0.95 (0.38–2.37) p = 0.92 | 0.28 (0.08-0.96) p = 0.04b |
| Death ≤12 mo, n (%) | 1 (5) | 6 (9.4) | 0.55 (0.06–4.84) p = 0.587 | 0.54 (0.04–6.8) p = 0.451b |
| MS after PML | ||||
| MS recurrence after PML, n (%) | 16 (80) | 27 (42.2) | 7.51 (1.99 to 28.33) p = 0.003 | 7.22 (1.73-30.2) p = 0.007c |
| Follow-up duration in months, median (IQR25-75) | 24 (8.7–40) | 13.6 (12–34.6) | — | — |
Abbreviations: mRS = modified Rankin scale; NTZ = natalizumab; S1P-RM = sphingosine-1-phosphate receptor modulators.
a
Corrected for sex and age at PML onset.
b
Corrected for sex, age at PML onset, JC virus load, asymptomatic presentation, plurilocular presentation, and mRS before PML.
c
Corrected for sex, age at PML onset, previous use of immunosuppressive therapies, and mRS before PML.